



## **Vivoryon Therapeutics to Host Virtual Event on Current Clinical Landscape in Alzheimer's Disease Treatment Options with Leaders and Experts on April 15<sup>th</sup>, 2021**

**HALLE (SAALE) / MUNICH, GERMANY, 1 April 2021** – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (**Vivoryon**) announced today that it will host a virtual event covering next steps in Alzheimer's Disease (AD) treatment options with leaders and experts in the field on Thursday, April 15<sup>th</sup>, 2021 from 5:00 - 7:00 pm CEST / 11:00 am - 1:00 pm EDT / 8:00 - 10:00 am PDT.

Despite repeated clinical trial failures in the AD space, a determined group of pharma and biotech companies has not given up on seeking for therapies that address the high unmet medical need in this indication. Vivoryon's interactive session will cover discussions surrounding current hurdles and exciting, novel approaches to the challenging AD space, including the company's clinical phase 2 compound, varoglutamstat, a small molecule inhibitor of glutaminyl cyclase (QC) capable of targeting all three hallmarks of AD: amyloid-beta, tau, and neuroinflammation.

### **Addressing the Alzheimer's Disease Puzzle in the Clinic: An Expert Overview**

Participating AD experts include:

**Professor Philip Scheltens**, MD, PhD, Director at the Alzheimer Center Amsterdam and Managing Partner of the LSP Dementia Fund, will provide a general overview of the AD space and which approaches show promise in this complex indication.

**Howard Feldman**, MD, Professor, Department of Neurosciences and Director of the Alzheimer's Disease Cooperative Study at the University of California San Diego School of Medicine, will give a presentation of VIVA-MIND, a Phase 2a US National Institutes on Aging-funded trial of varoglutamstat planned to start later this year.

**Frank Weber**, MD, Chief Medical Officer at Vivoryon, will discuss VIVIAD, Vivoryon's European Alzheimer's Disease Phase 2b study with varoglutamstat.

The speakers will be available for a Q&A session at the conclusion of the event.

The event will be accessible via a live webcast through [this link](#). A replay of the event will be available on Vivoryon's website following the presentation.

###

### **For more information, please contact:**

**Vivoryon Therapeutics N.V.**

Dr. Ulrich Dauer, CEO

Email: [contact@vivoryon.com](mailto:contact@vivoryon.com)



### **Trophic Communications**

Gretchen Schweitzer / Valeria Fisher

Tel: +49 172 861 8540 or +49 175 8041816

Email: [vivoryon@trophic.eu](mailto:vivoryon@trophic.eu)

### **About Vivoryon Therapeutics N.V.**

With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon's scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon is advancing its lead product, varoglutamstat (PQ912), in Alzheimer's disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications. In addition, the company pursues a development program for Meprin protease inhibitors with potential therapeutic use in fibrotic diseases, cancer and acute kidney injury. [www.vivoryon.com](http://www.vivoryon.com)

### **Forward Looking Statements**

*Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics N.V. as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.*